{"id":"W2163898107","doi":"10.1016/j.oraloncology.2014.12.013","title":"A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer","year":2015,"lang":"en","type":"article","venue":"Oral Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":78,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hôpital Fleurimont","funders":"National Institute of Dental and Craniofacial Research; National Cancer Institute; Wellcome Trust","keywords":"Medicine; Docetaxel; Internal medicine; Neutropenia; Clinical endpoint; Oncology; Tolerability; Mucositis; Phases of clinical research; Febrile neutropenia; Head and neck cancer; Progression-free survival; Adverse effect; Cancer; Gastroenterology; Randomized controlled trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001243669,0.002013502,0.002639298,0.0004515884,0.0004493704,0.001100608,0.0009671882,0.001506534,0.007714189],"category_scores_gemma":[0.001106433,0.0008469502,0.001337425,0.0004903937,0.001477913,0.001127615,0.0004286448,0.003638983,0.001208515],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009870125,"about_ca_system_score_gemma":0.001605705,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001678267,"about_ca_topic_score_gemma":0.005373078,"domain_scores_codex":[0.9996042,0.000171596,0.00001764308,0.00008795785,0.00002475406,0.000093829],"domain_scores_gemma":[0.9995345,0.0001073454,0.00007183382,0.00004552105,0.00002260416,0.0002181446],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9527712,0.01252233,0.0009597549,0.0003982393,0.0005524743,0.00005899731,0.00009905749,0.0009781269,0.004483022,0.0002466789,0.001524485,0.02540566],"study_design_scores_gemma":[0.934033,0.06282656,0.001284156,0.00001269072,0.0002200363,0.00003565536,0.00002815704,0.0003783345,0.0003565624,0.000156724,0.000655451,0.00001266231],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9889549,0.001797494,0.0005063735,0.0007910279,0.0004906499,0.003451646,0.001280146,0.0001186413,0.002609031],"genre_scores_gemma":[0.9826189,0.002081898,0.001681251,0.001319177,0.00031622,0.003455903,0.002067247,0.00004436183,0.006414932],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007714189,"threshold_uncertainty_score":0.02580649,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03533366139137531,"score_gpt":0.3436311828887238,"score_spread":0.3082975214973485,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}